GrayBug Secures Worldwide Rights to Develop Proprietary Ophthalmic Drug Delivery Platforms


GrayBug raises $1mm from investors and is awarded a $200k grant to support research

Baltimore, MD – April 11, 2012 – GrayBug LLC announced today they have raised over $1 million in equity from investors and have successfully obtained the worldwide right to new technologies invented by GrayBug LLC co-founders Justin Hanes, Peter Campochiaro, and Peter McDonnell through a licensing deal with the John Hopkins University.

GrayBug was also awarded a $200k grant from The Maryland Biotechnology Center through their Biotech Development Program to support development of the company’s lead product targeting Age Related Macular Degeneration (AMD).

GrayBug is a biotechnology company that is developing proprietary controlled release technologies for pharmaceutical indications. The company’s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases of the eye. GrayBug’s proprietary platform technology allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye.

Related News

Press release

Graybug Vision Appoints Frédéric Guerard as Chief Executive Officer Pharmaceutical Industry Veteran and Former Worldwide Business Franchise Head of Ophthalmology at Novartis

Redwood City, CA – February 5, 2019 – Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative therapies for ocular diseases, today announced that the Board of Directors has appointed Frédéric Guerard as Read more…

Press release

Graybug Vision Presents Top Line Results of Phase 1/2a ADAGIO Study at Hawaiian Eye & Retina 2019

ADAGIO Study Provides Evidence that GB-102 Can Achieve Sustained-Drug Delivery in the Treatment of Wet Age-Related Macular Degeneration (AMD) • Graybug Vision’s novel investigational depot approach is designed to continuously inhibit activity of all VEGF Read more…

Press release

Graybug Vision Announces Presentations on Novel Treatments for Wet AMD and Glaucoma at ARVO 2018 Annual Meeting

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Graybug Vision, Inc., a clinical stage pharmaceutical company committed to developing potentially transformative therapies for vision-threatening ocular diseases including wet age-related macular degeneration (wet AMD) and primary open angle glaucoma (POAG), today Read more…